Biomarkers
ROS1 Fusion
Also known as: ROS1 rearrangement, ROS1-positive
Definition
A chromosomal rearrangement involving the ROS1 gene, targetable with ROS1 inhibitors in lung cancer.
Detailed Explanation
ROS1 rearrangements occur in 1-2% of NSCLC, with similar patient demographics to ALK-positive disease. Respond to crizotinib, entrectinib, and other TKIs. Brain metastases are common, so CNS-penetrant drugs are preferred. Testing is typically by FISH or NGS due to low prevalence.